Sophie Taillibert

Summary

Country: France

Publications

  1. pmc Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma
    Alexandre Carpentier
    Department of Neurology, Hopital de la Salpetriere, Paris, France
    Neuro Oncol 8:60-6. 2006
  2. ncbi Chemobrain: is systemic chemotherapy neurotoxic?
    Sophie Taillibert
    Mazarin Neurology Unit, Salpetriere Hospital, Paris VI University, Paris, France
    Curr Opin Oncol 19:623-7. 2007
  3. doi Up-front temozolomide in elderly patients with anaplastic oligodendroglioma and oligoastrocytoma
    François Ducray
    AP HP, Groupe Hospitalier Pitie Salpetriere, Service de Neurologie Mazarin, Hopital de la Salpetriere, 47 Boulevard de l Hopital, 75013, Paris, France
    J Neurooncol 101:457-62. 2011
  4. ncbi Treatment of central nervous system metastases: parenchymal, epidural, and leptomeningeal
    Sophie Taillibert
    Neurology Department Mazarin, Hopital Salpetriere, Paris, France
    Curr Opin Oncol 18:637-43. 2006
  5. doi Bevacizumab and irinotecan for recurrent oligodendroglial tumors
    S Taillibert
    Service de Neurologie Mazarin, AP HP, Hopital de la Salpetriere, Paris, France
    Neurology 72:1601-6. 2009
  6. ncbi Is systemic anti-cancer therapy neurotoxic? Does chemo brain exist? And should we rename it?
    Sophie Taillibert
    Groupe Hospitalier Pitie Salpetriere, Service de Neurologie Mazarin, bâtiment Mazarin 47 bd de I hôpital, 75013, Paris, France
    Adv Exp Med Biol 678:86-95. 2010
  7. ncbi Loss of 14q chromosome in oligodendroglial and astrocytic tumors
    Charles Dichamp
    Unité INSERM U495, Paris, France
    J Neurooncol 67:281-5. 2004
  8. ncbi Dynamic history of low-grade gliomas before and after temozolomide treatment
    Damien Ricard
    Institut National de la Sante et de la Recherche Medicale, U711, Paris, France
    Ann Neurol 61:484-90. 2007
  9. doi Genomic changes in progression of low-grade gliomas
    Ahmed Idbaih
    INSERM Unité 711, Paris, France
    J Neurooncol 90:133-40. 2008
  10. doi Nitrosourea-based chemotherapy for low grade gliomas failing initial treatment with temozolomide
    Gentian Kaloshi
    AP HP, Université Pierre et Marie Curie UPMC, Service de Neurologie Mazarin, Groupe Hospitalier Pitie Salpetriere, Paris, France
    J Neurooncol 100:439-41. 2010

Collaborators

Detail Information

Publications30

  1. pmc Phase 1 trial of a CpG oligodeoxynucleotide for patients with recurrent glioblastoma
    Alexandre Carpentier
    Department of Neurology, Hopital de la Salpetriere, Paris, France
    Neuro Oncol 8:60-6. 2006
    ..2 months. In conclusion, CpG-28 was well tolerated at doses up to 20 mg per injection in patients with recurrent glioblastoma. Main side effects were limited to transient worsening of neurological condition and fever...
  2. ncbi Chemobrain: is systemic chemotherapy neurotoxic?
    Sophie Taillibert
    Mazarin Neurology Unit, Salpetriere Hospital, Paris VI University, Paris, France
    Curr Opin Oncol 19:623-7. 2007
    ..We still do not know which cytotoxic agents are responsible, which characteristics make patients vulnerable, and which biologic mechanisms are involved...
  3. doi Up-front temozolomide in elderly patients with anaplastic oligodendroglioma and oligoastrocytoma
    François Ducray
    AP HP, Groupe Hospitalier Pitie Salpetriere, Service de Neurologie Mazarin, Hopital de la Salpetriere, 47 Boulevard de l Hopital, 75013, Paris, France
    J Neurooncol 101:457-62. 2011
    ..Further investigation is needed to determine whether this treatment is preferable to initial radiation therapy...
  4. ncbi Treatment of central nervous system metastases: parenchymal, epidural, and leptomeningeal
    Sophie Taillibert
    Neurology Department Mazarin, Hopital Salpetriere, Paris, France
    Curr Opin Oncol 18:637-43. 2006
    ..With prolonged survival from systemic therapies in the adjuvant and salvage setting, and because these agents cannot cross the intact blood-brain barrier, central nervous system metastases are becoming a therapeutic challenge in oncology...
  5. doi Bevacizumab and irinotecan for recurrent oligodendroglial tumors
    S Taillibert
    Service de Neurologie Mazarin, AP HP, Hopital de la Salpetriere, Paris, France
    Neurology 72:1601-6. 2009
    ..Treatment with a regimen of bevacizumab-irinotecan has been shown to be effective in recurrent grade 3 and 4 gliomas, but the effect of this regimen against recurrent oligodendroglial tumors has not been specifically studied...
  6. ncbi Is systemic anti-cancer therapy neurotoxic? Does chemo brain exist? And should we rename it?
    Sophie Taillibert
    Groupe Hospitalier Pitie Salpetriere, Service de Neurologie Mazarin, bâtiment Mazarin 47 bd de I hôpital, 75013, Paris, France
    Adv Exp Med Biol 678:86-95. 2010
    ..Better-designed future trials should lead to a better definition and understanding of chemo brain and to future therapies...
  7. ncbi Loss of 14q chromosome in oligodendroglial and astrocytic tumors
    Charles Dichamp
    Unité INSERM U495, Paris, France
    J Neurooncol 67:281-5. 2004
    ..Loss of 14q was not correlated to survival, histological grading and subtype or other genetic alterations, except for 1p deletions. Taken together, these data suggest that LOH14q is an early alteration involving 20% of glioma...
  8. ncbi Dynamic history of low-grade gliomas before and after temozolomide treatment
    Damien Ricard
    Institut National de la Sante et de la Recherche Medicale, U711, Paris, France
    Ann Neurol 61:484-90. 2007
    ..To evaluate the natural progression and the impact of temozolomide in low-grade gliomas and to correlate these changes with the profile of genetic alterations...
  9. doi Genomic changes in progression of low-grade gliomas
    Ahmed Idbaih
    INSERM Unité 711, Paris, France
    J Neurooncol 90:133-40. 2008
    ..21%). Interestingly, putative novel candidate genes associated with glioma progression were identified, in particular DOCK8, PTPRD, CER1, TPHO, DHFR, MSH3, ETS1, ACACA, and CSE1L...
  10. doi Nitrosourea-based chemotherapy for low grade gliomas failing initial treatment with temozolomide
    Gentian Kaloshi
    AP HP, Université Pierre et Marie Curie UPMC, Service de Neurologie Mazarin, Groupe Hospitalier Pitie Salpetriere, Paris, France
    J Neurooncol 100:439-41. 2010
    ....
  11. ncbi Proton magnetic resonance spectroscopy predicts proliferative activity in diffuse low-grade gliomas
    Remy Guillevin
    Department of Neuroradiology, Pitie Salpetriere Hospital, Paris, France
    J Neurooncol 87:181-7. 2008
    ..05). This study suggests that (1)HMRS is a reliable tool to evaluate the proliferation activity of WHO grade 2 glioma and to identify potentially more aggressive clinical behavior...
  12. ncbi FABP7 expression in glioblastomas: relation to prognosis, invasion and EGFR status
    Gentian Kaloshi
    Service de Neurologie Mazarin, Assistance Publique Hopitaux de Paris, Groupe Hospitalier Pitie Salpetriere, and INSERM, U711, Biologie des Interactions Neurones and Glie, Faculte de Medecine, Universite Pierre et Marie Curie, Paris, Cedex 13, 75651, France
    J Neurooncol 84:245-8. 2007
    ....
  13. ncbi Leptomeningeal metastases from solid malignancy: a review
    Sophie Taillibert
    Federation de Neurologie, Batîment Mazarin, Groupe Hospitalier Pitie Salpetriere, 47 83 Bd de l Hopital, 75013, Paris, France
    J Neurooncol 75:85-99. 2005
    ..The overall prognosis remains grim and quality of life should remain the priority when deciding which treatment option to apply. However, a sub-group of patients, tentatively defined here, may benefit from an aggressive treatment...
  14. ncbi [Therapeutic strategies and prospects of gliomas]
    Sophie Taillibert
    Fédération de Neurologie Mazarin, Batîment Mazarin, Hopital Salpetriere, 47 83 Bd de l Hopital, 75013, Paris
    Presse Med 33:1278-83. 2004
    ..Chemotherapy has a modest efficacy in glioblastomas, whereas oligodendrogliomas with 1p 19q deletion are chemosensitive tumors...
  15. ncbi Gliomatosis cerebri: a review of 296 cases from the ANOCEF database and the literature
    Sophie Taillibert
    Federation de Neurologie, Groupe Hospitalier Pitie Salpetriere, 47 83 Bd de l Hopital, 75651, Paris, Cedex 13, France
    J Neurooncol 76:201-5. 2006
    ..Up-front chemotherapy benefit to some patients and may be preferred to whole brain radiotherapy. However, the many bias of such retrospective heterogeneous data claim for multicentric clinical trials in this rare disease...
  16. ncbi Dural metastases
    Florence Laigle-Donadey
    Fédération de Neurologie Mazarin, Groupe Hospitalier Pitie Salpetriere, 47 Boulevard de l Hopital, 75651, Paris Cedex 13, France
    J Neurooncol 75:57-61. 2005
    ..The prognosis is poor because of the progressive systemic cancer but prolonged survival has been reported in operated patients, when the systemic cancer was controlled...
  17. ncbi Brain lymphoma: usefulness of the magnetic resonance spectroscopy
    Sophie Taillibert
    Department of Neuro Oncology, Pitie Salpetriere Hospital, 47 83 boulevard de l Hopital, Paris, France
    J Neurooncol 86:225-9. 2008
    ..The case we report here illustrates the contribution of magnetic resonance spectroscopy in the diagnostic approach of a very atypical PCNSL...
  18. doi [Central nervous system complications in patients undergoing cytotoxic chemotherapy and targeted therapies]
    Dimitri Psimaras
    Hopital Pitie Salpetriere, Service de Neurologie Mazarin, Paris, France
    Bull Cancer 99:851-63. 2012
    ....
  19. ncbi Palliative care in patients with brain metastases
    Sophie Taillibert
    Service de Neurologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Curr Opin Oncol 17:588-92. 2005
    ..This article reviews all the supportive care measures in patients with brain metastases, with the exception of tumor-specific chemotherapy treatments that are also used in this patient population...
  20. ncbi Analysis of the bHLH transcription factors Olig1 and Olig2 in brain tumors
    Lucinda Aguirre-Cruz
    INSERM U495, Laboratoire de Biologie des Interactions Neurones Glie, Paris, France
    J Neurooncol 67:265-71. 2004
    ..Because Olig genes have a crucial role in oligodendroglial determination, our data could be of help in defining the real spectrum of oligodendroglial tumors...
  21. ncbi Skull-base metastases
    Florence Laigle-Donadey
    Fédération de Neurologie Mazarin, Groupe Hospitalier Pitie Salpetriere, 47 Boulevard de l Hopital, 75651, Paris Cedex 13, France
    J Neurooncol 75:63-9. 2005
    ..The overall prognosis is poor, with an overall median survival of about 2.5 years, probably because skull-base metastases appear late in the course of the disease...
  22. doi A multicenter prospective observational study of the conformity of temozolomide prescriptions in France
    Patrick Tilleul
    Department of Pharmacy, Pitie Salpetriere Hospital, Paris, France
    Pharmacoepidemiol Drug Saf 21:828-34. 2012
    ..The main objective of this study was to evaluate the conformity of TMZ prescriptions to the French SPC and prescription guidebook...
  23. ncbi [Current classification of gliomas]
    Sophie Taillibert
    Fédération de Neurologie Mazarin, Batîment Mazarin, Hopital Salpetriere, 47 83 Bd de l Hopital, 75013, Paris
    Presse Med 33:1274-7. 2004
    ..Newly identified good prognostic markers (1p and 19q loss in oligodendrogliomas) and new molecular techniques such as microarray may further refine the existing classification...
  24. ncbi Palliative care in patients with primary brain tumors
    Sophie Taillibert
    Service de Neurologie, Groupe Hospitalier Pitie Salpetriere, 47 83 boulevard de l Hopital, 75013 Paris, France
    Curr Opin Oncol 16:587-92. 2004
    ..This review updates available data on supportive care in patients with brain tumor...
  25. ncbi Prognostic value of allelic losses and telomerase activity in meningiomas
    Pascal Leuraud
    Laboratoire de Biologie des Interactions Neurones Glie, Institut Nationale de la Santé et de la Recherche Médicale U 495, Service de Neurochirurgie, Fédération de Neurologie Mazarin, Groupe Hospitalier Pitie Salpetriere, Paris, France
    J Neurosurg 100:303-9. 2004
    ..The goal of this study was to examine allelic losses and telomerase activity in meningiomas to determine whether they could be used to predict disease recurrence...
  26. ncbi Oxaliplatin plus irinotecan and FU-FOL combination and pharmacokinetic analysis in advanced colorectal cancer patients
    Marian A Gil-Delgado
    SOMPS, Salpetriere Hospital, Paris, France
    Am J Clin Oncol 27:294-8. 2004
    ..It would appear that the dose and schedule defined by this trial could be proposed as front-line therapy for advanced colorectal carcinoma to establish rapid disease control and to permit patients to proceed to surgery...
  27. ncbi [Improving the prognosis of glioma]
    Marc Sanson
    Fédération de Neurologie Mazarin, Hopital de la Salpetriere, Paris 75
    Presse Med 33:1267. 2004
  28. ncbi [The genetics of glioma: molecular classification]
    Sophie Taillibert
    Fédération de Neurologie Mazarin, Batîment Mazarin, Hopital Salpetriere, 47 83 Bd de l Hopital, 75013 Paris
    Presse Med 33:1268-73. 2004
    ..Genetic profile is not only of diagnostic--but also prognostic relevance, as shown by 1p associated to 19q loss in oligodendrogliomas which is predictive of better prognosis and higher response rate...
  29. ncbi Metastatic tumors of the nervous system
    Sophie Taillibert
    J Neurooncol 75:1-3. 2005
  30. ncbi Metastatic melanoma: chemotherapy
    Emilio Bajetta
    Medical Oncology Unit B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
    Semin Oncol 29:427-45. 2002
    ..New chemotherapeutic and biologic agents are now available and promising combined approaches targeting the tumor by several different mechanisms are desirable and will probably represent the future modality of treatment...